Composition containing ceramide-type compounds

Abstract

To provide a stable composition that can deliver or provide ceramide-type compounds to the deep layers of the skin. [Solution] The present invention relates to a composition comprising (a) at least one ceramide-type compound, (b) at least one fatty compound selected from the group consisting of (b1) fatty acids, (b2) fatty alcohols, and mixtures thereof, and (c) at least one compound selected from the group consisting of (c1) polysaccharides, (c2) glycolipids, (c3) polyamino acids and their salts, (c4) proteins, and mixtures thereof, wherein the composition can form or contains at least one microneedle having a width of 100 μm or less, preferably 50 μm or less, and more preferably 10 μm or less, and the microneedle contains (a) the ceramide-type compound. The composition according to the present invention is stable and can deliver or provide the (a) ceramide-type compound to the deep layers of the skin.

Description

[Technical Field]

[0001] The present invention relates to a composition comprising at least one ceramide-type compound, and a cosmetic method using the composition. [Background technology]

[0002] Ceramides present in the stratum corneum of the skin form a lipid barrier necessary for retaining moisture and play a crucial role in maintaining moisture within the skin. Ceramides in the stratum corneum are produced by the breakdown of cerebrosides by an enzyme known as cerebrosidase. Ceramides are then partially converted into phytosphingosine and sphingosine by the enzyme known as ceramidase. Phytosphingosine and sphingosine play important roles in regulating cell proliferation and differentiation. Six different types of ceramides, each with distinct functions, exist in human skin.

[0003] On the other hand, microneedle patches and dispersed microneedle formulations have been developed to deliver cosmetic active ingredients to the deeper layers of the skin. These microneedles can penetrate deep into the skin, sometimes even beyond the stratum corneum, thereby delivering cosmetic active ingredients to the deeper layers of the skin.

[0004] In addition, the formulation of environmentally friendly cosmetics, designed and developed with environmental issues in mind, is becoming a major goal in addressing global challenges.

[0005] Therefore, it is essential to propose more sustainable compositions, preparation methods, and ingredients to address these environmental problems.

[0006] In this context, it is important to develop novel cosmetic compositions with a better carbon footprint, particularly by promoting the use of renewable raw materials and / or materials with a good index of naturalness and / or materials of natural origin. [Prior art documents] [Patent Documents]

[0007] [Patent Document 1] DE 4424530 [Patent Document 2] DE 4424533 [Patent Document 3] DE 4402929 [Patent Document 4] DE 4420736 [Patent Document 5] WO 95 / 23807 [Patent Document 6] WO 94 / 07844 [Patent Document 7] EP-A-0 646 572 [Patent Document 8] WO 95 / 16665 [Patent Document 9] FR-2 673 179 [Patent Document 10] EP-A-0 227 994 [Patent Document 11] WO 94 / 24097 [Patent Document 12] WO 94 / 10131 [Patent Document 13] EP-A-0500437 [Patent Document 14] EP-A-0647617 [Patent Document 15] WO03 / 068824 [Non-patent literature]

[0008] [Non-Patent Document 1] “The skin barrier: An extraordinary interface with an exceptional lipid organization”, Progress in Lipid Research 92 (2023) 101252, J Bouwstra et al., Figure 2, p. 4 [Non-Patent Document 2] D. Campoccia et al., "Semisynthetic resorbable materials from hyaluronan esterification", Biomaterials 19 (1998) pp. 2101-2127 [Non-Patent Document 3] AP Tulloch, JFT Spencer and PAJ Gorin, Can. J. Chem. (1962), 40, 1326. [Non-Patent Document 4] U. Gobbert, S. Lang and F. Wagner, Biotechnology Letters (1984), 6 (4), 225. [Non-Patent Document 5] D. Haferburg, R. Hommel, R. Claus, and HP Kleber, Adv. Biochem. Ing. / Biotechnol. (1986), pp. 33, 53-90. [Non-Patent Document 6] Fermentation (edited by RM Lafferty) by F. Wagner, H. Bock, and A. Kretschmar (1981), pp. 181-192, Springer Verlag, Vienna. [Overview of the Initiative] [Problems that the invention aims to solve]

[0009] There is a need to deliver ceramide-type compounds to the deeper layers of the skin.

[0010] On the other hand, because ceramides have low solubility in water, dispersions of ceramide-type compounds have been found to be unstable in some cases.

[0011] Therefore, there is another need to provide stable compositions containing ceramide-type compounds.

[0012] The object of the present invention is to provide a stable composition that can deliver or provide ceramide-type compounds to the deep layers of the skin. [Means for solving the problem]

[0013] The above objective of the present invention is, (a) at least one ceramide-type compound, (b) At least one fatty compound selected from the group consisting of (b1) fatty acids, (b2) fatty alcohols, and mixtures thereof, (c) At least one compound selected from the group consisting of (c1) polysaccharides, (c2) glycolipids, (c3) polyamino acids and their salts, (c4) proteins, and mixtures thereof. A composition comprising, preferably a cosmetic composition, more preferably a skin cosmetic composition, The composition can form or contains at least one microneedle having a width of 100 μm or less, preferably 50 μm or less, and more preferably 10 μm or less. Microneedles can be achieved by a composition comprising (a) a ceramide-type compound.

[0014] The microneedles may further contain (b) a fatty compound and (c) a compound.

[0015] The microneedles may have an aspect ratio of 4 or more, preferably 6 or more, and more preferably 8 or more.

[0016] (a) Ceramide-type compounds are given by the following formula (I):

[0017] [ka]

[0018] [In the formula, - R1 represents a linear or branched saturated or unsaturated hydrocarbon group C1~C 50 , preferably C5~C 50 , which group may be substituted with one or more hydroxyl groups, and / or may optionally be interrupted by one or more oxycarbonyl (-O-CO-) groups or carbonyloxy (-CO-O-) groups, - R2 represents a linear or branched saturated or unsaturated hydrocarbon group C1~C 50 , preferably C5~C 50 , which group may be substituted with one or more hydroxyl groups, and / or may optionally be interrupted by one or more oxycarbonyl (-O-CO-) groups or carbonyloxy (-CO-O-) groups] can be represented by.

[0019] The amount of the (a) ceramide-type compound in the composition according to the present invention may be 0.001 mass% to 10 mass%, preferably 0.005 mass% to 5 mass%, more preferably 0.01 mass% to 1 mass%, relative to the total mass of the composition.

[0020] (b1) The fatty acid can be selected from C4~C 24 , preferably C6~C 22 , more preferably C8~C 20 saturated or unsaturated linear or branched fatty acids.

[0021] (b2) The fatty alcohol can be selected from C4~C 24 , preferably C6~C 22 , more preferably C8~C 20 saturated and unsaturated linear or branched fatty alcohols.

[0022] The amount of (b) fatty compound in the composition according to the present invention may be 0.01% to 15% by mass, preferably 0.05% to 10% by mass, and more preferably 0.1% to 5% by mass, based on the total mass of the composition.

[0023] (c1) The polysaccharide may be selected from the group consisting of chitosan, hyaluronic acid and its derivatives, polysaccharides derived from microorganisms, and mixtures thereof, preferably from the group consisting of chitosan, hyaluronic acid and its salts, xanthan gum, and mixtures thereof.

[0024] (c2) The glycolipid may be selected from the group consisting of rhamnolipids, sophorolipids, and mixtures thereof, preferably from rhamnolipids.

[0025] (c3) Polyamino acids can be selected from polyglutamic acids.

[0026] (c4) The protein may be of plant origin.

[0027] The amount of compound (c) in the composition according to the present invention may be 0.001% to 15% by mass, preferably 0.005% to 10% by mass, and more preferably 0.01% to 5% by mass, based on the total mass of the composition.

[0028] The present invention also relates to a cosmetic method for keratinous substances such as skin, Steps of applying the composition according to the present invention to a keratin substance. This also includes information about beauty methods.

[0029] The present invention also, (a) at least one ceramide-type compound A microneedle containing, The present invention also relates to microneedles having a width of 100 μm or less, preferably 50 μm or less, and more preferably 10 μm or less.

[0030] The microneedle according to the present invention is (b) At least one fatty compound selected from the group consisting of (b1) fatty acids, (b2) fatty alcohols, and mixtures thereof, (c) At least one compound selected from the group consisting of (c1) polysaccharides, (c2) glycolipids, (c3) polyamino acids and their salts, (c4) proteins, and mixtures thereof, It may also include the following. [Brief explanation of the drawing]

[0031] [Figure 1] This is a micrograph obtained by microscopic observation of the composition according to Example 1. [Figure 2] This is a micrograph obtained by microscopic observation of the composition according to Example 2. [Figure 3] This is a micrograph obtained by microscopic observation of the composition according to Example 3. [Figure 4] This is a micrograph obtained by microscopic observation of the composition according to Example 4. [Figure 5] This is a micrograph obtained by microscopic observation of the composition according to Example 5. [Figure 6] This is a micrograph obtained by microscopic observation of the composition according to Example 6. [Figure 7] This is a micrograph obtained by microscopic observation of the composition according to Example 7. [Figure 8] This is a micrograph obtained by microscopic observation of the composition according to Example 8. [Figure 9] This is a micrograph obtained by microscopic observation of the composition according to Example 9. [Modes for carrying out the invention]

[0032] As a result of diligent research, the inventors have discovered that it is possible to provide a stable composition that can deliver or provide ceramide-type compounds to the deep layers of the skin.

[0033] Therefore, the composition according to the present invention is (a) at least one ceramide-type compound, (b) At least one fatty compound selected from the group consisting of (b1) fatty acids, (b2) fatty alcohols, and mixtures thereof, (c) At least one compound selected from the group consisting of (c1) polysaccharides, (c2) glycolipids, (c3) polyamino acids and their salts, (c4) proteins, and mixtures thereof. Includes.

[0034] The composition according to the present invention can form or contain at least one microneedle having a width of 100 μm or less, preferably 50 μm or less, and more preferably 10 μm or less, wherein the microneedle contains (a) a ceramide-type compound.

[0035] (a) a ceramide-type compound, (b) a fatty compound, and (c) a compound can form a complex in the form of a needle. The width of the needle is very small, i.e., it is so-called micro-sized, with a width of 100 μm or less, preferably 50 μm or less, and more preferably 10 μm or less. Therefore, the needle is referred to as a microneedle.

[0036] The length of the microneedles may be several micrometers or several hundred micrometers. Therefore, the aspect ratio of the microneedles may be 4 or greater, 6 or greater, and more preferably 8 or greater. The width and length of the microneedle morphology complex can be measured by an optical microscope. This width and length may be based on a number-average width or length.

[0037] (a) Ceramide-type compounds are difficult to dissolve or disperse in water, for example. Therefore, (a) ceramide-type compounds tend to crystallize and form aggregates or precipitates.

[0038] However, the above-mentioned complex, at least containing the (a) ceramide-type compound in the form of microneedles, can be stably dispersed in water, for example. Therefore, the composition according to the present invention is so stable that it does not form any aggregates or precipitates based on the (a) ceramide-type compound, or forms only very small amounts of aggregates or precipitates based on the (a) ceramide-type compound.

[0039] (a) Ceramide-type compounds are known to function as moisturizers that can impart a moist or wet feeling, and / or as whitening agents that can whiten or lighten keratinous substances such as skin. In addition, (a) ceramide-type compounds are also known to improve the barrier effect of keratinous substances such as skin.

[0040] Therefore, the composition according to the present invention can provide various cosmetic effects derived from (a) ceramide-type compounds, such as skin moisturizing effect, skin whitening effect, and skin protective effect, for example, when the stratum corneum is damaged by dry skin.

[0041] Furthermore, by attaching microneedles containing (a) ceramide-type compounds to the skin, the composition according to the present invention can deliver (a) ceramide-type compounds more deeply and effectively to the skin. Therefore, the composition according to the present invention can provide or deliver (a) ceramide-type compounds to the deeper layers of the skin. Consequently, it is possible to enhance the inherent properties of (a) ceramide-type compounds, such as the moisturizing effect of the skin and the strengthening of the skin's barrier function.

[0042] (a) Ceramide-type compounds and / or (b) fatty compounds and / or (c) compounds may be of natural origin, renewable materials, and biodegradable. Therefore, compositions according to the present invention may contain environmentally friendly components.

[0043] The present invention will be described in more detail below.

[0044] [Composition] The composition according to the present invention is (a) at least one ceramide-type compound, (b) At least one fatty compound selected from the group consisting of (b1) fatty acids, (b2) fatty alcohols, and mixtures thereof, (c) At least one compound selected from the group consisting of (c1) polysaccharides, (c2) glycolipids, (c3) polyamino acids and their salts, (c4) proteins, and mixtures thereof. Includes, The composition can form or contains at least one microneedle having a width of 100 μm or less, preferably 50 μm or less, and more preferably 10 μm or less. The microneedles contain (a) a ceramide-type compound.

[0045] The microneedle contains at least (a) a ceramide-type compound.

[0046] The microneedles may further contain (a) a ceramide-type compound, as well as (b) a fatty compound and (c) a compound. In this case, compound (c) may form the surface of the microneedles.

[0047] The microneedles in the composition according to the present invention are in the form of very small needles, such that the width of the microneedles is 100 μm or less, preferably 50 μm or less, and more preferably 10 μm or less.

[0048] The minimum width of the microneedle is not limited and may be 0.1 μm or more, preferably 0.3 μm or more, and more preferably 0.5 μm or more.

[0049] Therefore, the width of the microneedle may be 0.1 μm to 100 μm, preferably 0.3 μm to 50 μm, and more preferably 0.5 μm to 10 μm.

[0050] The microneedle may have a certain width. Alternatively, the end of the microneedle may have a conical shape.

[0051] The microneedle may have an aspect ratio (length / width) of 4 or more, preferably 6 or more, and more preferably 8 or more.

[0052] The length of the microneedle is not limited and may be several micrometers or several hundred micrometers. Therefore, there is no upper limit to the aspect ratio of the microneedle. For example, the aspect ratio of the microneedle may be 100 or less, preferably 50 or less, and more preferably 10 or less.

[0053] The microneedles may be linear, curved, or bent nonlinear. A linear shape for the microneedles is preferred.

[0054] (Ceramide-type compounds) The composition according to the present invention comprises (a) at least one ceramide-type compound. A single type of ceramide-type compound or a combination of different types of ceramide-type compounds can be used.

[0055] (a) Ceramide-type compounds can form complexes with (b) lipid compounds and (c) compounds.

[0056] According to the present invention, the term "ceramide-type compound" is understood to mean natural or synthetic ceramides and / or glycoceramides and / or pseudoceramides and / or neoceramides.

[0057] Ceramide-type compounds are disclosed, for example, in patent applications DE 4424530, DE 4424533, DE 4402929, DE 4420736, WO 95 / 23807, WO 94 / 07844, EP-A-0 646 572, WO 95 / 16665, FR-2 673 179, EP-A-0 227 994, WO 94 / 24097 and WO 94 / 10131, as well as in the publication "The skin barrier: An extraordinary interface with an exceptional lipid organization," Progress in Lipid Research 92 (2023) 101252, J Bouwstra et al., in Figures 2 and 4, and these teachings are incorporated herein by reference.

[0058] (a) Ceramide-type compounds are defined by the following general formula (I):

[0059] [ka]

[0060] [In the formula, - R1 is a linear or branched saturated or unsaturated hydrocarbon group C1~C 50 Preferably C5~C 50 This represents a group which may be substituted with one or more hydroxyl groups and / or optionally interrupted with one or more oxycarbonyl (-O-CO-) groups or carbonyloxy (-CO-O-) groups. - R2 is a linear or branched saturated or unsaturated hydrocarbon group C1~C 50 Preferably C5~C 50 This represents a group which may be substituted with one or more hydroxyl groups and / or optionally interrupted by one or more oxycarbonyl (-O-CO-) groups or carbonyloxy (-CO-O-) groups. It can be represented by [this].

[0061] In preferred embodiments, (a) the ceramide-type compound is a compound of formula (I) [wherein R1 is a linear or branched saturated or unsaturated hydrocarbon group C]. 14 ~C 22 Preferably C 14 ~C 20 For example, C 15 or C 16 or C 17 This represents a group which may be substituted with one or more hydroxyl groups and / or optionally interrupted with one or more oxycarbonyl (-O-CO-) or carbonyloxy (-CO-O-) groups, where R2 is a linear or branched saturated or unsaturated hydrocarbon group C 14 ~C 22 Preferably C 14 ~C 20 For example, C 15 This represents a group which may be substituted with one or more hydroxyl groups and / or may be optionally interrupted by an oxycarbonyl (-O-CO-) group or a carbonyloxy (-CO-O-) group.

[0062] In preferred embodiments, (a) the ceramide-type compound is a compound of formula (I) [wherein R1 is a linear or branched saturated or unsaturated hydrocarbon group C]. 15 or C 16 or C 17 This represents a group which may be substituted with one or more hydroxyl groups and / or optionally interrupted with one or more oxycarbonyl (-O-CO-) groups or carbonyloxy (-CO-O-) groups, where R2 is a linear or branched saturated or unsaturated hydrocarbon group C 15 This represents a group which may be substituted with one or more hydroxyl groups and / or may be optionally interrupted by an oxycarbonyl (-O-CO-) group or a carbonyloxy (-CO-O-) group.

[0063] Such compounds include, for example, - 2-N-Linoleoylamino-octadecane-1,3-diol, - N-oleoyldihydrosphingosine (INCI), - 2-N-palmitoylamino-octadecane-1,3-diol, - 2-N-stearoylamino-octadecane-1,3-diol, - 2-N-[2-hydroxy-palmitoyl]-amino-octadecane-1,3-diol, - 2-N-stearoylamino-octadecane-1,3,4triol, especially N-stearoylphytosphingosine, - 2-N-palmitoylamino-hexadecane-1,3-diol, Or a mixture of these compounds.

[0064] According to a preferred embodiment, the composition according to the present invention preferably comprises (a) at least one ceramide-type compound selected from ceramides NdS, AdS, OdS, EOdS, NS, AS, OS, EOS, NG, AG, NP, AP, OP, EOP, NH, AH, OH, EOH, NSD, ASD, OSD, EOSD, NT, BS, EO-18:2, EO-18:1, hydroxypalmitoyl sphinganine, 2-oleamide-1,3-octadecanediol, and mixtures thereof.

[0065] According to a preferred embodiment, the composition according to the present invention comprises (a) at least one ceramide-type compound selected from ceramides NS, AS, OS, EOS, NP, AP, OP, EOP, hydroxypalmitoyl sphinganine, 2-oleamide-1,3-octadecanediol, and mixtures thereof.

[0066] According to a preferred embodiment, the composition according to the present invention comprises (a) at least one ceramide-type compound selected from ceramide NS, AS, EOS, NP, AP, EOP, hydroxypalmitoyl sphinganine, 2-oleamide-1,3-octadecanediol, and mixtures thereof, and more preferably selected from ceramide NS, AS, EOS, NP, AP, EOP, and mixtures thereof.

[0067] According to a preferred embodiment, the composition according to the present invention preferably comprises at least two ceramide-type compounds selected from ceramides NS, AS, EOS, NP, AP, and EOP.

[0068] According to a preferred embodiment, the composition according to the present invention preferably comprises two ceramide-type compounds selected from a mixture of ceramides (NS and AS) or (NS and EOS), or (NS and NP), or (NS and AP), or (NS and EOP), or (AS and EOS), or (AS and NP), or (AS and EOP), or (EOS and NP), or (EOS and AP), or (EOS and EOP), or (NP and AP), or (NP and EOP), or (AP and EOP).

[0069] According to a preferred embodiment, the composition according to the present invention comprises at least three ceramide-type compounds selected from ceramides NS, AS, EOS, NP, AP, and EOP.

[0070] According to a preferred embodiment, the composition according to the present invention preferably comprises three ceramide-type compounds selected from ceramides (NS, AS, and EOS), or (NS, AS, and NP), or (NS, AS, and AP), or (NS, AS, and EOP), or (AS, EOS, and NP), or (AS, EOS, and AP), or (AS, EOS, and EOP), or (EOS, NP, and AP), or (NP, AP, and EOP).

[0071] According to a preferred embodiment, the composition according to the present invention comprises at least four ceramide-type compounds selected from ceramides NS, AS, EOS, NP, AP, and EOP.

[0072] According to a preferred embodiment, the composition according to the present invention preferably comprises four ceramide-type compounds selected from ceramides (NS and AS and EOS and NP), or (NS and AS and EOS and AP), or (NS and AS and EOS and EOP), or (NS and EOS and NP and AP), or (NS and EOS and NP and EOP), or a mixture of (NS and NP and AP and EOP).

[0073] According to a preferred embodiment, the composition according to the present invention comprises at least five ceramide-type compounds selected from ceramides NS, AS, EOS, NP, AP, and EOP.

[0074] According to a preferred embodiment, the composition according to the present invention preferably comprises five ceramide-type compounds selected from ceramides (NS and AS and EOS and NP and AP) or (NS and AS and EOS and NP and EOP) or a mixture of (AS and EOS and NP and AP and EOP).

[0075] According to a preferred embodiment, the composition according to the present invention preferably comprises one, two, three, or four ceramide-type compounds selected from ceramides NS, AS, EOS, NP, AP, and EOP.

[0076] The synthesis of ceramides is described, for example, in EP-A-0500437 and EP-A-0647617.

[0077] Hydroxypalmitoyl sphinganine is a well-known and commercially available product.

[0078] 2-Oleamido-1,3-Octadecanediol is a known product and is commercially available.

[0079] Ceramide NP, also known as N-stearoyl-phytosphingosine, is a well-known and commercially available product.

[0080] Ceramide AP, also known as N-(2-hydroxystearoyl)phytosphingosine, is a well-known and commercially available product.

[0081] Ceramide EOP, also known as stearoyloxyheptacosanoyl-C27-phytosphingosine or 30-[[(1S,2S,3R)-2,3-dihydroxy-1-(hydroxymethyl)heptadecyl]amino]-30-oxotriacontyl(9Z,12Z)-9,12-octadecadienoate, is a well-known and commercially available product.

[0082] Ceramide NdS, also known as N-tetracosanoyl sphinganine, is a well-known and commercially available product.

[0083] Ceramide AdS, also known as 2-hydroxy-N-[(1S,2R)-2-hydroxy(hydroxymethyl)heptadecyl]tetracosaneamide, is a well-known and commercially available product.

[0084] Ceramide EOdS is a well-known product also known as 9,12-octadecadienoic acid (9Z,12Z)-,30-[[(1S,2R)-2-hydroxy-1-(hydroxymethyl)heptadecyl]amino]-30-oxotriacontyl ester.

[0085] Ceramide NS is also known as N-stearoyl sphinganin.

[0086] Ceramide AS, also known as 2-hydroxy-N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecene-1-yl]tetracosaneamide, is a well-known product that is commercially available.

[0087] Ceramide EOS is a well-known product also known as 9,12-octadecadienoic acid (9Z,12Z)-,30-[[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecene-1-yl]amino]-30-oxotriacontyl ester.

[0088] Ceramide NG, also known as N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecene-1-yl]octadecanamide or N-octadecanoylsphingosine, is a well-known and commercially available product.

[0089] Ceramide NH is a well-known product also known as N-[(1S,2R,3E)-2,5-dihydroxy-1-(hydroxymethyl)-3-heptadecene-1-yl]tetracosaneamide.

[0090] Ceramide AH is a well-known product also known as N-[(1S,2R,3E)-2,5-dihydroxy-1-(hydroxymethyl)-3-heptadecene-1-yl]-2-hydroxytetracosamide.

[0091] Ceramide EOH is a well-known product also known as 30-[[(1S,2R,3E)-2,5-dihydroxy-1-(hydroxymethyl)-3-heptadecene-1-yl]amino]-30-oxotriacontyl(9Z,12Z)-9,12-octadecadienoate.

[0092] (a) The ceramide-type compound may preferably be selected from the group consisting of ceramide AP, ceramide NP, ceramide EOP, and mixtures thereof.

[0093] (a) The ceramide-type compound may more preferably be ceramide NP, ceramide AP, or a mixture thereof.

[0094] The amount of (a) ceramide-type compound in the composition according to the present invention may be 0.001% by mass or more, preferably 0.005% by mass or more, and more preferably 0.01% by mass or more, based on the total mass of the composition.

[0095] On the other hand, the amount of (a) ceramide-type compound in the composition according to the present invention may be 10% by mass or less, preferably 5% by mass or less, and more preferably 1% by mass or less, based on the total mass of the composition.

[0096] Therefore, the amount of (a) ceramide-type compound in the composition according to the present invention may be 0.001% to 10% by mass, preferably 0.005% to 5% by mass, and more preferably 0.01% to 1% by mass, based on the total mass of the composition.

[0097] In one embodiment of the present invention, the composition is - A first ceramide selected from ceramide AP, NP, EOP, AS, NS, and EOS in an amount of at least 0.0001% to 5% by mass, preferably 0.001% to 1% by mass, and more preferably 0.005% to 0.1% by mass, relative to the total mass of the composition. - A second ceramide selected from ceramide AP, NP, EOP, AS, NS, and EOS in an amount of at least 0.0001% to 5% by mass, preferably 0.001% to 1% by mass, and more preferably 0.005% to 0.1% by mass, relative to the total mass of the composition. - A third ceramide selected from AP, NP, EOP, AS, NS, and EOS in an amount of at least 0.000001% to 1% by mass, preferably 0.000005% to 0.01% by mass, and more preferably 0.000007% to 0.001% by mass, relative to the total mass of the composition. The first, second, and third ceramides are distinct from each other.

[0098] (fatty compound) The composition according to the present invention comprises at least one fatty compound selected from the group consisting of (b)(b1) fatty acids, (b2) fatty alcohols, and mixtures thereof.

[0099] (b) The fatty compound can form a complex with (a) the ceramide-type compound and (c) the compound.

[0100] In this specification, the term "lipid compound" refers to an organic compound having a long aliphatic carbon chain.

[0101] (b) The fatty compound has at least 4 carbon atoms, preferably at least 6 carbon atoms, more preferably at least 8 carbon atoms. (b) The fatty compound may contain up to 24 carbon atoms, preferably up to 22 carbon atoms, more preferably up to 20 carbon atoms.

[0102] The amount of (b) fatty compound in the composition according to the present invention may be 0.01% by mass or more, preferably 0.05% by mass or more, and more preferably 0.1% by mass or more, based on the total mass of the composition.

[0103] On the other hand, the amount of (b) fatty compound in the composition according to the present invention may be 15% by mass or less, preferably 10% by mass or less, and more preferably 5% by mass or less, based on the total mass of the composition.

[0104] Therefore, the amount of (b) fatty compound in the composition according to the present invention may be in the range of 0.01% to 15% by mass, preferably 0.05% to 10% by mass, and more preferably 0.1% to 5% by mass, relative to the total mass of the composition.

[0105] (b1) Fatty acids The composition according to the present invention may (b1) contain at least one fatty acid. A single type of fatty acid or a combination of different types of fatty acids can be used.

[0106] In this specification, the term "fatty acid" refers to a carboxylic acid having a long aliphatic carbon chain.

[0107] (b1) The fatty acid has at least 4 carbon atoms, preferably at least 6 carbon atoms, more preferably at least 8 carbon atoms. (b1) The fatty acid may contain up to 24 carbon atoms, preferably up to 22 carbon atoms, more preferably up to 20 carbon atoms. (b1) The fatty acid is C4~C 24 Fatty acids, more like C6~C 22 Fatty acids, more preferably C8-C 20 It is preferable to select from fatty acids.

[0108] (b1) fatty acids can be selected from saturated or unsaturated, linear or branched fatty acids. Therefore, (b1) fatty acids are C 10 ~C 20 Preferably C 12 ~C 20 , more C 14 ~C 20 They can be selected from saturated or unsaturated linear or branched fatty acids.

[0109] As unsaturated linear or branched fatty acids, monounsaturated linear or branched fatty acids or polyunsaturated linear or branched fatty acids may be used. Examples of the unsaturated portion of unsaturated linear or branched fatty acids include carbon-carbon double bonds or carbon-carbon triple bonds.

[0110] Examples of saturated fatty acids include caprylic acid (C8), pelargonic acid (C9), and capric acid (C8). 10 ), lauric acid (C 12 ), myristic acid (C 14 ), pentadecanoic acid (C 15 ), palmitic acid (C 16 ), heptadecanoic acid (C 17 ), stearic acid (C 18 ), isostearic acid (C 18 ), nonadecanoic acid (C 19 ), arachidic acid (C 20 ), behenic acid (C 22 ), and lignoceric acid (C 24 ) can be cited.

[0111] Examples of unsaturated fatty acids include myristoleic acid (C 14 ), palmitoleic acid (C 16 ), oleic acid (C 18 ), linoleic acid (C 18 ), linolenic acid (C 18 ), elaidic acid (C 18 ), arachidonic acid (C 20 ), eicosenoic acid (C 20 ), erucic acid (C 22 ), and nervonic acid (C 24 ) can be cited.

[0112] (b1) Fatty acids are C 16 ~C 18 From saturated or unsaturated linear or branched fatty acids, it is preferable to select from the group consisting of oleic acid, linoleic acid, linolenic acid, palmitic acid, stearic acid, isostearic acid, and mixtures thereof.

[0113] (b1) Fatty acids may be in the form of their free acid or their salt. Examples of fatty acid salts include inorganic salts, such as alkali metal salts (sodium salts, potassium salts, etc.) and alkaline earth metal salts (magnesium salts, calcium salts, etc.), and organic salts, such as ammonium salts (quaternary ammonium salts, etc.) and amine salts (triethanolamine salts, triethylamine salts, etc.). A single type of fatty acid salt or a combination of different types of fatty acid salts may be used. Furthermore, a combination of one or more fatty acids in the form of free acids and one or more fatty acids in the form of salts may be used, and one or more types of salts may also be used.

[0114] The amount of (b1) fatty acid in the composition according to the present invention may be 0.01% by mass or more, preferably 0.05% by mass or more, and more preferably 0.1% by mass or more, based on the total mass of the composition.

[0115] On the other hand, the amount of (b1) fatty acid in the composition according to the present invention may be 15% by mass or less, preferably 10% by mass or less, and more preferably 5% by mass or less, based on the total mass of the composition.

[0116] Therefore, the amount of (b1) fatty acid in the composition according to the present invention may be in the range of 0.01% to 15% by mass, preferably 0.05% to 10% by mass, and more preferably 0.1% to 5% by mass, relative to the total mass of the composition.

[0117] (b2) Fatty alcohols The composition according to the present invention may (b) contain at least one fatty alcohol. A single type of fatty alcohol or a combination of different types of fatty alcohols can be used.

[0118] The term "fatty" in this specification refers to the inclusion of a relatively large number of carbon atoms. Therefore, alcohols having four or more, preferably six or more, and more preferably eight or more carbon atoms are included in the range of fatty alcohols. Fatty alcohols may contain up to 24 carbon atoms, preferably up to 22, and more preferably up to 20 carbon atoms. Fatty alcohols may be saturated or unsaturated. Fatty alcohols may be linear or branched.

[0119] (b2) Fatty alcohols may have the structure R-OH (wherein R is selected from saturated and unsaturated, linear and branched groups containing 4 to 24 carbon atoms, e.g., 8 to 22 carbon atoms). In at least one embodiment, R is C 12 ~C 24 Alkyl and C 12 ~C 24 The group is selected from alkenyl groups. R may or may not be substituted with at least one hydroxyl group.

[0120] (b2) Fatty alcohols are C4~C 24 Preferably C6~C 22 , more preferably C8~C20 A selection may be made from saturated or unsaturated linear or branched fatty alcohols.

[0121] (b2) Non-limiting examples of fatty alcohols that can be listed include lauryl alcohol, cetyl alcohol, stearyl alcohol, oleyl alcohol, behenyl alcohol, linoleyl alcohol, undecylenyl alcohol, palmitrail alcohol, arachidonyl alcohol, erucyl alcohol, cetearyl alcohol, and mixtures thereof.

[0122] Suitable examples of (b2) fatty alcohols include, but are not limited to, cetyl alcohol, cetearyl alcohol, stearyl alcohol, behenyl alcohol, oleyl alcohol, and mixtures thereof.

[0123] (b2) Fatty alcohol may represent a mixture of fatty alcohols, meaning that several types of fatty alcohols can coexist in the form of a mixture in commercially available products. According to at least one embodiment, the fatty alcohol used in the composition according to the present invention is selected from a mixture of cetyl alcohol and stearyl alcohol (cetearyl alcohol).

[0124] The amount of (b2) fatty alcohol in the composition according to the present invention may be 0.01% by mass or more, preferably 0.05% by mass or more, and more preferably 0.1% by mass or more, based on the total mass of the composition.

[0125] On the other hand, the amount of (b2) fatty alcohol in the composition according to the present invention may be 15% by mass or less, preferably 10% by mass or less, and more preferably 5% by mass or less, based on the total mass of the composition.

[0126] Therefore, the amount of (b2) fatty alcohol in the composition according to the present invention may be in the range of 0.01% to 15% by mass, preferably 0.05% to 10% by mass, and more preferably 0.1% to 5% by mass, relative to the total mass of the composition.

[0127] (compounds that form complexes) The composition according to the present invention comprises at least one compound selected from the group consisting of (c) (c1) polysaccharides, (c2) glycolipids, (c3) polyamino acids and their salts, (c4) proteins, and mixtures thereof.

[0128] (c) Compounds are different from (a) ceramide-type compounds and (b) fatty compounds.

[0129] (c) The compound can form complexes with (a) ceramide-type compounds and (b) fatty compounds.

[0130] (c1) Polysaccharides, (c2) Glycolipids, (c3) Polyamino acids and their salts, and (c4) Proteins are distinct from one another.

[0131] The amount of compound (c) in the composition according to the present invention may be 0.001% by mass or more, preferably 0.005% by mass or more, and more preferably 0.01% by mass or more, based on the total mass of the composition.

[0132] On the other hand, the amount of compound (c) in the composition according to the present invention may be 15% by mass or less, preferably 10% by mass or less, and more preferably 5% by mass or less, based on the total mass of the composition.

[0133] Therefore, the amount of compound (c) in the composition according to the present invention may be in the range of 0.001% to 15% by mass, preferably 0.005% to 10% by mass, and more preferably 0.01% to 5% by mass, relative to the total mass of the composition.

[0134] (c1) Polysaccharide The composition according to the present invention may contain (c1) at least one polysaccharide. A single type of polysaccharide or a combination of different types of polysaccharides can be used.

[0135] (c1) The polysaccharide is preferably derived from natural resources such as plants and microorganisms.

[0136] It is more preferable that the (c1) polysaccharide is biodegradable. The term "biodegradable" means that the (c1) polysaccharide can be broken down or divided in the environment or in living organisms, for example, by metabolism by microorganisms that may be present in the environment or in living organisms. Furthermore, biodegradable (c1) polysaccharides can be broken down by hydrolysis.

[0137] (c1) The polysaccharide may be nonionic or ionic, preferably ionic, more preferably cationic or anionic.

[0138] Cationic (C1) polysaccharides may have a positive charge density. The charge density of cationic (C1) polysaccharides may be 0.01 meq / g to 20 meq / g, preferably 0.05 meq / g to 15 meq / g, and more preferably 0.1 meq / g to 10 meq / g.

[0139] Anionic (C1) polysaccharides may have a negative charge density. The charge density of anionic (C1) polysaccharides may be 0.1 meq / g to 5.0 meq / g, preferably 0.2 meq / g to 4.0 meq / g, and more preferably 0.3 meq / g to 3.0 meq / g.

[0140] (c1) Examples of polysaccharides include chitosan, hyaluronic acid and their derivatives, as well as biopolysaccharides, which are described below.

[0141] Chitosan: (c1) The polysaccharide can be selected from chitosan.

[0142] In one embodiment, chitosan may have a low molecular weight.

[0143] The molecular weight (Da) of chitosan may be 1,000 or more, preferably 2,000 or more, and more preferably 3,000 or more. On the other hand, the molecular weight (Da) of chitosan may be less than 20,000, preferably less than 15,000, and more preferably less than 10,000.

[0144] Therefore, the molecular weight (Da) of the low molecular weight chitosan may be greater than 1,000 and less than 20,000, preferably greater than 2,000 and less than 15,000, and more preferably greater than 3,000 and less than 10,000.

[0145] In another embodiment, chitosan may have a high molecular weight.

[0146] The molecular weight (Da) of chitosan may be greater than 20,000, preferably greater than 50,000, and more preferably greater than 80,000. On the other hand, the molecular weight (Da) of chitosan may be less than 1,000,000, preferably less than 500,000, and more preferably less than 300,000.

[0147] Therefore, the molecular weight (Da) of the high molecular weight chitosan may be greater than 20,000 and less than 1,000,000, preferably greater than 50,000 and less than 500,000, and more preferably greater than 80,000 and less than 300,000.

[0148] Unless otherwise defined in the description, "molecular weight" refers to the mass-average molecular weight. Molecular weight can be measured or determined by gel permeation chromatography, for example, in accordance with ASTM D5296-19.

[0149] Chitosan is extremely rare in nature. It has only been reported in the exoskeleton of certain insects, such as termite queens, and in the cell walls of certain types of fungi, specifically those belonging to the class Zygomycetes.

[0150] Chitosan can be obtained by the deacetylation of chitin. Chitin is a polysaccharide composed of several N-acetyl-D-glucosamine units linked together by β-linkages (1,4).

[0151] The ideal chemical structure of chitosan is a sequence of β-D-glucosamine monomers linked by glycosidic bonds (1→4).

[0152] The "chitosan" according to the present invention refers to any copolymer formed from the constituent units N-acetyl-D-glucosamine and D-glucosamine, wherein the degree of acetylation is less than 90%, preferably less than 80%, preferably less than 70%, preferably less than 60%, and preferably less than 50%. Chitosan consists of glucosamine sugar units (deacetylated units) and N-acetyl-D-glucosamine units (acetylated units) linked together by β-type bonds (1,4), and is a poly(N-acetyl-D-glucosamine)-poly(D-glucosamine) type polymer.

[0153] More preferably, the degree of acetylation of chitosan is 40% or less, preferably 35% or less, preferably 25% or less, preferably 15% or less, and preferably 10% or less.

[0154] The degree of acetylation is the percentage of acetylated units relative to the total number of units, and can be determined by Fourier transform infrared spectroscopy (FT-IR) or titration with a strong base.

[0155] The chitosan of the present invention is preferably a polysaccharide prepared from a fungal source. In particular, it is extracted and purified from a safe and abundant food or biotechnological fungal source, such as mushroom (Agaricus bisporus) or black mold (Aspergillus niger).

[0156] The chitosan of the present invention is preferably derived from fungi of the Ascomycete class, particularly Aspergillus and / or Basidiomycetes, specifically the mycelium of Lentinula edodes (shiitake) and / or button mushrooms. Preferably, the fungus is Aspergillus.

[0157] Chitosan may be of genetically modified organism (GMO) origin, but is preferably of non-GMO origin.

[0158] The chitosan according to the present invention is natural, that is, unmodified. In particular, it contains no chemical modifications whatsoever.

[0159] One method for preparing chitosan is described in WO03 / 068824.

[0160] Preferably, the chitosan used in the present invention is in powder form. It is commercially available from Kitozyme under the names Kiosmetine or Kionutrime, for example, Kiosmetine-CSH and Kiosmetine P.

[0161] Hyaluronic acid and its derivatives: (c1) The polysaccharide can be selected from hyaluronic acid and its derivatives.

[0162] Hyaluronic acid can be represented by the following chemical formula:

[0163] [ka]

[0164] In the context of this invention, the term "hyaluronic acid" specifically refers to the following formula:

[0165] [ka]

[0166] It contains the basic unit of hyaluronic acid. This is the smallest part of hyaluronic acid, which includes disaccharide dimers, namely D-glucuronic acid and N-acetylglucosamine.

[0167] In the context of this invention, the term "hyaluronic acid" refers to a linear polymer comprising the polymer units described above, linked together in the chain via alternating β(1,4) and β(1,3) glucosidic bonds, having a molecular weight (Mw) that can range between 380 and 13,000,000 daltons. This molecular weight depends primarily on the source and / or preparation method from which the hyaluronic acid is obtained.

[0168] The term "hyaluronic acid" also includes hydrolyzed hyaluronic acid in the context of this invention.

[0169] In the context of this invention, the term "hyaluronic acid and its derivatives" includes hyaluronic acid salts. Examples of salts include alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as magnesium salts, ammonium salts, and mixtures thereof. Sodium hyaluronate is preferred.

[0170] The term "hyaluronic acid and its derivatives" also, in the context of the present invention, includes hyaluronic acid esters, in particular hyaluronic acid esters in which all or part of the carboxylic acid group of the acidic functional group is esterified with an oxyethylene alkyl or alcohol containing 1 to 20 carbon atoms, and especially hyaluronic acid esters in which the degree of substitution at the level of D-glucuronic acid of hyaluronic acid is in the range of 0.5% to 50%.

[0171] In particular, methyl, ethyl, n-propyl, n-pentyl, benzyl, and dodecyl esters of hyaluronic acid can be mentioned. Such esters are described in detail in D. Campoccia et al., "Semisynthetic resorbable materials from hyaluronan esterification," Biomaterials 19 (1998), pp. 2101-2127.

[0172] In one embodiment, the hyaluronic acid derivative may be, for example, acetylated hyaluronic acid or a salt thereof.

[0173] The term "hyaluronic acid and its derivatives" also includes cationic hyaluronic acid in the context of this invention.

[0174] Cationic hyaluronic acid contains at least one cationic moiety. The cationic moiety is -N + The cationic moiety may be a trialkylammonium group such as (CH3)3. The cationic moiety may contain at least one hydroxyl group. An example of a cationic group is -CH2-CH(OH)-CH2-N + (CH3)3 is one example.

[0175] An example of a cationic hyaluronic acid is hydroxypropyltrimonium hyaluronate.

[0176] The molecular weight of hyaluronic acid and its derivatives is not limited. The molecular weight of hyaluronic acid and its derivatives may be 5 kDa or more, preferably 20 kDa or more, and more preferably 100 kDa or more. The molecular weight of hyaluronic acid and its derivatives may be 20 MDa or less, preferably 10 MDa or less, and more preferably 2,000 kDa or less. Therefore, the molecular weight of hyaluronic acid and its derivatives may be 5 kDa to 20 MDa, preferably 20 kDa to 10 MDa, and more preferably 100 kDa to 2,000 kDa.

[0177] Unless otherwise defined in the explanation, "molecular weight" can refer to the mass-average molecular weight.

[0178] Hyaluronic acid or its derivatives, in particular, are supplied by Centipro under the trade name HyActive® (Mw: 10-150kDa), by Givaudan under the trade name Cristalhyal® (Mw: 1-1.4MDa), by Bioland under the trade name Nutra®HA (Mw: 907,600Da), by Bioland under the trade name Nutra®HAF (Mw: 74,600Da), by Bioland under the trade name Oligo®HA (Mw: 0.5-10.1kDa), by Res Pharma under the trade name D-Factor® (Mw: 380Da), or by Bloomage Freda Biopharm under the trade name Hybloom®Sodium Hyaluronate It may also be supplied under the product name (HA-T)(MW:1,000kDa~1,800kDa).

[0179] A single hyaluronic acid or its derivative having a single molecular weight, or a combination of two or more hyaluronic acids or their derivatives having different molecular weights, can be used.

[0180] Hyaluronic acid or its derivatives are preferably selected from hyaluronic acid salts, more preferably alkali metal hyaluronic acid salts, and even more preferably sodium hyaluronate.

[0181] Biopolysaccharides: In one embodiment, the (c1) polysaccharide can be selected from polysaccharides derived from microorganisms, known as biopolysaccharides.

[0182] Microbial polysaccharides or biopolysaccharides refer to polysaccharides produced by microorganisms such as pathogenic bacteria or other microorganisms. Microbial polysaccharides can be produced through the fermentation of sugars mediated by microorganisms.

[0183] Polysaccharides derived from microorganisms may contain units selected from mannose units, glucose units, and glucuronic acid units or galacturonic acid units within their chains, and these units may be acylated.

[0184] In particular, xanthan gum produced by the bacterium Xanthomonas campestris, as well as its variants and variants, can be mentioned.

[0185] Furthermore, scleroglucan gum produced by Sclerotium rolfsii, gellan gum produced by Pseudomonas elodea or Sphingomonias, pulllan gum produced by Aureobacidium pullulens, curdlan gum produced by Alcaligenes of the Faecalis myxogenes type, dextran gum produced by numerous organisms including Leuconostoc mesenteroides and Leuconostoc dextrantum, grifolan gum produced by Maitake mushroom (Grifola frondara), and lentinan gum produced by Shiitake mushroom (Lentinus edodes). Other examples include schizophyllan gum produced by Schizophyllum commine, spirulinan gum produced by Spirulina sybsyla, and cresting gum produced by Coriates versicolor.

[0186] The polysaccharides derived from microorganisms may be chemically modified at the discretion of the user.

[0187] According to certain embodiments of the present invention, polysaccharides derived from microorganisms are modified. In particular, nonionic guar gum modified with C1-C6 (poly)hydroxyalkyl groups can be cited.

[0188] Examples of hydroxyalkyl groups include hydroxymethyl, hydroxyethyl, hydroxypropyl, and hydroxybutyl groups.

[0189] These guar gums are well known in the prior art and can be prepared, for example, by reacting the guar gum with the corresponding alkene oxide, such as propylene oxide, to obtain guar gum modified with a hydroxypropyl group.

[0190] The degree of (poly)hydroxyalkylation corresponds to the number of alkylene oxide molecules consumed by the number of free hydroxyl functional groups present on the guar gum, and is preferably in the range of 0.4 to 1.2.

[0191] Nonionic guar gums optionally modified with such hydroxyalkyl groups are sold by Rhodia Chimie under trade names such as Jaguar HP8, Jaguar HP60 and Jaguar HP120, Jaguar DC 293, and Jaguar HP 105, or by Aqualon under the name Galactasol 4H4FD2.

[0192] Examples of polysaccharides derived from microorganisms include cardran, xanthan gum, gellan gum, dextran, pullulan, sclerotium gum, and mixtures thereof.

[0193] It may be preferable that the polysaccharide derived from microorganisms be selected from the group consisting of sclerotium gum, xanthan gum, and mixtures thereof.

[0194] (c1) The polysaccharide is preferably selected from chitosan, hyaluronic acid and their derivatives, polysaccharides derived from microorganisms, and mixtures thereof.

[0195] (c1) The polysaccharide is more preferably selected from chitosan, hyaluronic acid and their salts, xanthan gum, and mixtures thereof.

[0196] (c1) It is even more preferable that the polysaccharide is selected from high molecular weight chitosan, hyaluronic acid and sodium hyaluronate, xanthan gum, and mixtures thereof.

[0197] The amount of (c1) polysaccharide in the composition according to the present invention may be 0.001% by mass or more, preferably 0.005% by mass or more, and more preferably 0.01% by mass or more, based on the total mass of the composition.

[0198] On the other hand, the amount of (c1) polysaccharide in the composition according to the present invention may be 15% by mass or less, preferably 10% by mass or less, and more preferably 5% by mass or less, based on the total mass of the composition.

[0199] Therefore, the amount of (c1) polysaccharide in the composition according to the present invention may be 0.001% to 15% by mass, preferably 0.005% to 10% by mass, and more preferably 0.01% to 5% by mass, based on the total mass of the composition.

[0200] (c2) Glycolipid The composition according to the present invention may contain (c2) at least one glycolipid. A single type of glycolipid or a combination of different types of glycolipids can be used.

[0201] The term "glycolipid" is understood to mean a compound formed from lipids to which one or more sugar compounds are bonded.

[0202] According to the present invention, the (c2) glycolipid is selected from sophorolipid, rhamnolipid, and mixtures thereof, more preferably from rhamnolipid.

[0203] Sophorolipid: (c2) Glycolipids contain a sophorose moiety and have the general formula (II):

[0204] [ka]

[0205] (In the formula, - R 3 and R 4 Each represents a hydrogen atom or an acetyl group. - R 5 This represents a saturated or unsaturated hydroxylated or unhydroxylated hydrocarbon group having 1 to 9 carbon atoms, preferably methyl. - R 6 This represents a saturated or unsaturated hydroxylated or unhydroxylated hydrocarbon group having 1 to 19 carbon atoms. However, R 5 and R 6 The total number of carbon atoms in the group shall not exceed 20, preferably 14 to 18. - R 7 This represents a hydrogen atom, - R 8 This represents the hydroxyl group OH. or R 7 and R 8 (They form a lactone ring together.) A sophorolipid may be selected from those that can be represented by the following:

[0206] Sophorolipid is R 7 represents a hydrogen atom, R 8 The form of an open-chain free acid in which the hydroxyl group OH represents, or formula (III):

[0207] [ka]

[0208] (In the formula, - R3 , R 4 , R 5 , and R 6 are as defined above, provided that R 3 and R 4 at least one of which represents an acetyl group) can be incorporated into the composition according to the present invention in any of its lactone forms, wherein the lactone ring is formed between R 7 and R 8 as indicated by

[0209] Sophorolipids can be produced by yeast cells, for example, Torulopsis apicola and Torulopsis bombicola cells. The fermentation process generally uses sugars and alkanes as substrates.

[0210] Suitable fermentation methods are outlined in A.P. Tulloch, J.F.T. Spencer and P.A.J. Gorin, Can. J. Chem. (1962), 40, 1326, and U. Gobbert, S. Lang and F. Wagner, Biotechnology Letters (1984), 6 (4), 225. The resulting product is a mixture of various open-chain sophorolipids and sophorolipid lactones, which may be used in the form of the mixture, or the desired form may be isolated.

[0211] Examples of sophorolipids that may be used include the product sold under the name Sopholiances by the company Givaudan and the product sold under the name BioToLife by the company BASF.

[0212] Rhamnolipids: (c2) The glycolipid can be selected from rhamnolipids.

[0213] The composition according to the present invention preferably comprises one or more rhamnolipids.

[0214] Rhamnolipids are glycolipids produced by various bacterial species. Rhamnolipids consist of one rhamnose fragment (monorhamnolipid) or two rhamnose fragments (diramnolipid) linked by glycosidic bonds to one, two, or three chains of β-hydroxylated fatty acids that are linked to each other by ester bonds.

[0215] Preferably, rhamnolipid is given by the following formula (VI):

[0216] [ka]

[0217] (In the formula, - m represents an integer equal to 2, 1, or 0. - n represents an integer equal to 1 or 0. - R1 and R2 each independently represent the same or different hydrocarbon group having 2 to 24 carbon atoms, preferably 5 to 13 carbon atoms, branched or unbranched, substituted or unsubstituted, particularly hydroxysubstituted, saturated or unsaturated, preferably monounsaturated, doublyunsaturated or tripunsaturated alkyl group. The corresponding monorhamnolipids and diramnolipids, as well as their salts, solvates, and optical isomers, can also be selected.

[0218] Therefore, when n is equal to 0, equation (VI) protects monoramnolipid, and when n is equal to 1, it protects diramnolipid.

[0219] The composition according to the present invention preferably comprises at least one diramnolipid.

[0220] The composition according to the present invention is preferably of formula (VI) (wherein, - m represents an integer equal to 2, 1, or 0. - n represents an integer equal to 1, - R1 and R2 each independently represent at least one diramnolipid of a branched or unbranched, substituted or unsubstituted, particularly hydroxysubstituted, saturated or unsaturated, identical or different hydrocarbon group, preferably monounsaturated, biunsaturated or tripunsaturated alkyl group, having 2 to 24 carbon atoms, preferably 5 to 13 carbon atoms, as well as salts thereof, solvates thereof, and optical isomers thereof.

[0221] The glycosidic bond between the two rhamnose fragments may be in an alpha configuration or a beta configuration, and is preferably in an alpha configuration.

[0222] In the context of the present invention, - The salts of diramnolipid of formula (VI) are, more specifically, carboxylate salts thereof with organic or inorganic cations, particularly cations selected from sodium, potassium, calcium, and ammonium. - The solvated form of the diram nolipid of formula (VI) is, more specifically, a solvated form with one or more molecules of water or an organic solvent, such as a hydrate or a solvate of a linear or branched alcohol such as ethanol or isopropanol, and the optically active carbon atom of the fatty acid is preferably in the form of an R enantiomer. - The term "alkyl" group refers to a saturated linear or branched aliphatic group; for example, a C1-C group having a linear or branched hydrocarbon chain of 1-20 carbon atoms. 20 Alkyl groups, more specifically, include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, or eicosyl.

[0223] The composition according to the present invention is preferably of formula (VI) [wherein, - m represents an integer equal to 2, 1, or 0. - n represents an integer equal to 1, - R1 and R2 are identical or different, and are selected from pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl and tridecenyl groups, and the formula -(CH2) o CH3 group (wherein o represents an integer in the range of 1 to 23, particularly 3 to 15, more specifically 4 to 12), at least one dirhamnolipid selected from the group consisting of

[0224] According to one embodiment of the present invention, the composition according to the present invention comprises at least one dirhamnolipid of general formula (VI) (wherein m is equal to 1).

[0225] According to one embodiment of the present invention, the composition according to the present invention comprises a mixture of at least 2, preferably at least 3 dirhamnolipids of general formula (VI) (wherein m is preferably equal to 1).

[0226] According to another embodiment of the present invention, the composition according to the present invention comprises a mixture containing at least one monorhamnolipid.

[0227] More preferably, the composition according to the present invention has the following formula (VII):

[0228] [Chemical formula]

[0229] [In the formula, - m represents an integer equal to 2, 1 or 0, preferably m is equal to 1, - n represents an integer equal to 1, - R1 is -(CH2) p -CH3 group (wherein p is an integer varying from 1 to 23, preferably 4 to 12), - R2 is -(CH2) q -CH3 group (wherein q is an integer varying from 1 to 23, preferably 4 to 12)] at least one dirhamnolipid, as well as salts, solvates and optical isomers thereof.

[0230] As non-limiting illustrations, in particular, of dirhamnolipids of formula (VII) that may be suitable for the present invention, mention may be made of compounds of formula di-RL-CXCY such as those defined in the table below.

[0231] The formula di-RL-CXCY is an alternative notation for representing a dirhamnolipid (di-RL) functionalized with two R1 and R2 groups respectively represented by the symbols CX and CY (the integers X and Y are equal to p+4 and q+4, respectively).

[0232] Table 1

[0233] According to a preferred embodiment, the composition according to the present invention comprises at least one dirhamnolipid of formula (VII) (wherein p and q are identical and equal to 6, and m is equal to 1) (also referred to as di-RL-C10C10), or one of the salts, solvates and optical isomers thereof.

[0234] Preferably, the dirhamnolipid of formula (VII) (wherein p and q are identical and equal to 6, and m is equal to 1) is present in the composition according to the present invention in a proportion of at least 50% by weight, preferably 51% to 85% by weight, relative to the total weight of the rhamnolipids.

[0235] According to a preferred embodiment, the composition according to the present invention comprises at least one dirhamnolipid of formula (VII) (wherein m is equal to 1, p is equal to 6, and q is equal to 8), or a salt, solvate or optical isomer thereof.

[0236] According to a preferred embodiment, the composition according to the present invention is of formula (VI) [wherein n and m are equal to 1, R1 is -(CH2) oThe compound comprises at least one diram nolipid, or a salt, solvate, or optical isomer thereof, wherein R1 represents a CH3 group (wherein o is an integer varying from 4 to 12), and R2 is selected from pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, and tridecenyl groups, preferably R1 represents a -(CH2)6CH3 group and R2 represents a nonenyl group.

[0237] According to a preferred embodiment, the composition according to the present invention comprises a mixture of at least two, and more particularly at least three, diramnolipids of the previously defined formula (VI) or formula (VII), more specifically selected from the following: - Diramnolipid of formula (VII) (where p and q are the same and equal to 6, and m is equal to 1), - Diramnolipid of formula (VII) (wherein m is equal to 1, p is equal to 6, and q is equal to 8), and - Equation (VI) [wherein n and m are equal to 1, and R1 is -(CH2)] o A dilam nolipid of at least one type, wherein R1 represents a CH3 group (wherein o is an integer varying from 4 to 12), and R2 is selected from pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, and tridecenyl groups, preferably R1 represents a -(CH2)6CH3 group and R2 represents a nonenyl group.

[0238] Preferably, the composition according to the present invention comprises a mixture of at least two, particularly at least three, diramnolipids of formula (VI) or formula (VII), selected from the following: - Diramnolipid of formula (VII) (wherein p and q are the same and equal to 6, and m is equal to 1) in an amount of at least 50% by mass, preferably 51% to 85% by mass, relative to the total mass of rhamnolipid. - Diramnolipid of formula (VII) (wherein p is equal to 6, q is equal to 8, and m is equal to 1) in an amount of 0.5% to 25% by mass, preferably 5% to 15% by mass, relative to the total mass of rhamnolipid, and - Diramnolipid of formula (VI) (wherein n and m are equal to 1, R1 represents a -(CH2)6CH3 group, and R2 represents a nonenyl group) in an amount of 0.5% to 15% by mass, preferably 3% to 12% by mass, and preferably 5% to 10% by mass, relative to the total mass of rhamnolipid.

[0239] Rhamnolipid is usually prepared from bacterial strains such as Pseudomonas by methods known to those skilled in the art.

[0240] Appropriate fermentation methods are outlined in Adv. Biochem. Ing. / Biotechnol. (1986), pp. 33, 53–90, by D. Haferburg, R. Hommel, R. Claus, and H.P. Kleber, and in Fermentation (edited by RM Lafferty) (1981), pp. 181–192, Springer Verlag, Vienna, by F. Wagner, H. Bock, and A. Kretschmar.

[0241] As rhamnolipid, you may use the product sold by Evonik under the name Rheance One (INCI name: glycolipid).

[0242] The amount of (c2) glycolipid in the composition according to the present invention may be 0.001% by mass or more, preferably 0.005% by mass or more, and more preferably 0.01% by mass or more, based on the total mass of the composition.

[0243] On the other hand, the amount of (c2) glycolipid in the composition according to the present invention may be 15% by mass or less, preferably 10% by mass or less, and more preferably 5% by mass or less, based on the total mass of the composition.

[0244] Therefore, the amount of (c2) glycolipid in the composition according to the present invention may be 0.001% to 15% by mass, preferably 0.005% to 10% by mass, and more preferably 0.01% to 5% by mass, relative to the total mass of the composition.

[0245] (c3) Polyamino acids or salts thereof The composition according to the present invention may contain (c3) at least one polyamino acid or a salt thereof. A single type of polyamino acid or a salt thereof may be used, or two or more different types of polyamino acids or salts thereof may be used in combination.

[0246] (c3) The polyamino acid is preferably selected from polyglutamic acid. Therefore, component (c3) in the composition according to the present invention is preferably at least one polyglutamic acid or a salt thereof.

[0247] Polyglutamic acid or its salts have the following chemical formula (1): ROOC-CH2CH2-CH(-COOR)-NH-[CO-CH2CH2-CH(-COOR)-NH-] n -CO-CH2CH2-CH(-COOR)-NH2(1) [In the formula, R independently represents an alkali metal atom such as a hydrogen atom, a sodium atom, or a potassium atom, or an ammonium group such as a tetramethylammonium group or a tetraethylammonium group. n is an integer of 2 or greater, preferably 4 or greater, and more preferably 6 or greater. It may have a chemical structure represented by [this].

[0248] The polyglutamic acid or its salt represented by the above chemical formula (1) may be called γ-polyglutamic acid or its salt because the carboxylic acid group at the γ position and the amino group at the α position form a peptide bond.

[0249] It is preferable that the polyglutamic acid or its salt has a molecular weight of 1000 or more and a degree of polymerization of 8 or more (where "n" in the above chemical formula (1) is 6 or more).

[0250] It may be more preferable that the polyglutamic acid or its salt has a molecular weight of 100,000 or more and a degree of polymerization of 770 or more (where "n" in the above chemical formula (1) is 768 or more).

[0251] It may be even more preferable that the polyglutamic acid or its salt has a molecular weight of 500,000 or more and a degree of polymerization of 3840 or more (where "n" in the above chemical formula (1) is 3838 or more).

[0252] There is no upper limit to the molecular weight of polyglutamic acid or its salts.

[0253] However, the molecular weight of polyglutamic acid or its salt may be 5,000,000 or less, and the degree of polymerization may be 38,500 or less (where "n" in the above chemical formula (1) is 38,498 or less). Preferably, the molecular weight of polyglutamic acid or its salt may be 3,000,000 or less, and the degree of polymerization may be 23,080 or less (where "n" in the above chemical formula (1) is 23,078 or less).

[0254] The glutamic acid that constitutes polyglutamic acid or its salts may be D-form, L-form, or racemic. However, considering market availability, biocompatibility, and biodegradability, it may be preferable to use polyglutamic acid composed solely of L-form glutamic acid or a mixture of L-form and D-form glutamic acid. However, polyglutamic acid composed of D-form glutamic acid, which has the same effect but is less degradable, can also be used.

[0255] The method for producing polyglutamic acid or its salts is not particularly limited. For example, it can be produced by organic synthesis using a peptide synthesizer, organic synthesis by polymerization of glutamic acid N-carboxy anhydride, or organic synthesis by polymerization of N-benzyloxycarbonylglutamic acid anhydride. On the other hand, microorganisms belonging to the genus Bacillus that have the ability to produce γ-polyglutamic acid (especially Bacillus subtilis, Bacillus anthracis, Bacillus licheniformis, and Bacillus megaterium) can also be used in fermentation methods for producing polyglutamic acid or its salts.

[0256] In addition to natural culture media composed of natural products such as shochu distillation wastewater culture media and soybean extract culture media, the following components are used as culture media in the fermentation method: Carbon sources such as glucose, fructose, galactose, sucrose, maltose, mannose, lactose, glycerol, and starch. Inorganic nitrogen sources such as ammonium sulfate, ammonium phosphate, and ammonium hydrochloride, Organic nitrogen sources such as glutamic acid or its salts, aspartic acid or its salts, Major inorganic salts such as sodium chloride, magnesium sulfate, monopotassium phosphate, phosphorus, and disodium hydrogen phosphate, Trace amounts of inorganic salts containing atoms such as iron, copper, zinc, cobalt, nickel, boron, manganese, molybdenum, tin, selenium, silicon, arsenic, vanadium, chromium, and fluorine. Vitamins such as biotin, nicotinamide, calcium pantothenate, thiamine, riboflavin, and pyridoxine hydrochloride. Organic acids such as citric acid, tartaric acid, malic acid, and glycolic acid, and Yeast extract, meat extract, potato extract, tomato extract, and natural product extracts such as soy peptides. Any synthetic medium or semi-synthetic medium consisting of any one of the following may be used at any concentration.

[0257] The microbial culture conditions may be set in the range of 20°C to 37°C in terms of temperature, and can be further controlled during the microbial growth process and the polyglutamic acid production process. The pH may be set in the range of 5.0 to 8.0, and can be further controlled during the microbial growth process and the polyglutamic acid production process.

[0258] After the completion of the culture, known methods such as acid precipitation, solvent precipitation, and membrane purification can be arbitrarily selected as methods for extracting and purifying polyglutamic acid or its salt from the culture medium.

[0259] It is preferable to use polyglutamic acid or its alkali metal salt, such as sodium polyglutamate, as the polyglutamic acid or its salt.

[0260] Commercially available products may be used as polyglutamic acid or its salts. Examples of polyglutamic acid or its salts include Hyafactor® PGA-HM, sold by Bloomage Biotechnology Co., Ltd. in China, and Bio-PGA Solution HE, HB, LB, and LE, as well as Bio PGA Na powder, sold by Ichimaru Falcos Co., Ltd. in Japan.

[0261] The amount of (c3) polyamino acids and / or salts thereof in the composition according to the present invention may be 0.001% by mass or more, preferably 0.005% by mass or more, and more preferably 0.01% by mass or more, based on the total mass of the composition.

[0262] On the other hand, the amount of (c3) polyamino acid or its salt in the composition according to the present invention may be 15% by mass or less, preferably 10% by mass or less, and more preferably 5% by mass or less, based on the total mass of the composition.

[0263] Therefore, the amount of (c3) polyamino acid and / or its salt in the composition according to the present invention may be 0.001% to 15% by mass, preferably 0.005% to 10% by mass, and more preferably 0.01% to 5% by mass, based on the total mass of the composition.

[0264] (c4) Protein The composition according to the present invention may contain (c4) at least one protein. A single type of protein may be used, or two or more different types of proteins may be used in combination.

[0265] (c4) The protein is preferably selected from plant-derived proteins. Therefore, component (c4) in the composition according to the present invention is preferably at least one plant-derived protein.

[0266] Plant-derived proteins may be polypeptides obtained from plants such as soybeans, peas, wheat, rice, corn, and sesame. The proteins may be hydrolyzed. Hydrolysis may be carried out, for example, by conventionally known methods using acids or enzymes. Plant-derived proteins may also be polypeptides obtained through industrial biotechnology methods such as genetic modification and fermentation of natural, powerful carbon sources such as cornstarch.

[0267] The plant-derived protein may be selected from the group consisting of hydrolyzed pea protein, hydrolyzed soy protein, hydrolyzed wheat protein, hydrolyzed rice protein, hydrolyzed corn protein, plant-derived recombinant silk protein, and mixtures thereof.

[0268] The plant-derived protein is preferably hydrolyzed pea protein.

[0269] The protein may contain acidic amino acids such as aspartic acid and glutamic acid, as well as basic amino acids such as arginine, histidine, and lysine.

[0270] Hydrolyzed pea protein can be prepared by hydrolysis of peas (Pisum sativum L). Commercial products such as Promois® WJ or Promois® WJ-SP manufactured by Seiwa Kasei Co., Ltd., which are aqueous solutions or powdered pea proteins with an average molecular weight of approximately 500, may be used as hydrolyzed pea protein. Hydrolyzed soy protein can be prepared by hydrolysis of soybeans (Glycine max). Commercial products such as Promois® WS or Promois® WS-HSP manufactured by Seiwa Kasei Co., Ltd., which are aqueous solutions or powdered soy proteins with an average molecular weight of approximately 700, may be used as hydrolyzed soy protein. Hydrolyzed wheat protein can be prepared by hydrolysis of wheat (Triticum). As hydrolyzed wheat protein, commercially available products such as Promois® WG or Promois® WG-SP manufactured by Seiwa Kasei Co., Ltd., which are aqueous solutions or powdered wheat protein with an average molecular weight of approximately 700, may be used. Hydrolyzed rice protein can be prepared by hydrolysis of rice (Oryza sativa). As hydrolyzed rice protein, commercially available products such as Promois® WR or Promois® WR-SP manufactured by Seiwa Kasei Co., Ltd., which are aqueous solutions or powdered rice protein with an average molecular weight of approximately 400, may be used. As a mixture of hydrolyzed wheat protein, hydrolyzed corn protein, and hydrolyzed soy protein, commercially available products such as Keraplant manufactured by TRI-K, which are aqueous solutions of wheat protein, corn protein, and soy protein, may be used. As plant-derived silk, commercially available products such as Silkgel Neo® manufactured by Givaudan, which is an aqueous gel silk produced by industrial biotechnology using fermentation, may be used.

[0271] Since the protein can be obtained from plants, the present invention can be environmentally friendly.

[0272] The amount of (c4) protein in the composition according to the present invention may be 0.001% by mass or more, preferably 0.005% by mass or more, and more preferably 0.01% by mass or more, based on the total mass of the composition.

[0273] On the other hand, the amount of (c4) protein in the composition according to the present invention may be 15% by mass or less, preferably 10% by mass or less, and more preferably 5% by mass or less, based on the total mass of the composition.

[0274] Therefore, the amount of (c4) protein in the composition according to the present invention may be 0.001% to 15% by mass, preferably 0.005% to 10% by mass, and more preferably 0.01% to 5% by mass, relative to the total mass of the composition.

[0275] (Skincare active ingredients) The composition according to the present invention may (d) contain at least one skincare active ingredient. A single type of skincare active ingredient or a combination of different types of skincare active ingredients can be used.

[0276] (d) Skin care active ingredients are different from (a) ceramide-type compounds, (b) fatty compounds, and (c) compounds.

[0277] (d) The skincare active ingredient is preferably a skincare beauty active ingredient, more preferably a skin peeling agent.

[0278] Examples of peeling agents include salicylic acid and its derivatives. Salicylic acid derivatives are given by formula (III):

[0279] [ka]

[0280] (In the formula, The R group represents a linear, branched, or cyclic saturated aliphatic chain containing 2 to 22 carbon atoms; an unsaturated chain containing 2 to 22 carbon atoms containing one or more conjugated double bonds; or an aromatic nucleus linked to a carbonyl group directly or via a saturated or unsaturated aliphatic chain containing 2 to 7 carbon atoms, wherein the group may be the same or different, and may be substituted by one or more substituents selected from (a) a halogen atom, (b) a trifluoromethyl group, (c) a hydroxyl group in its free form or esterified by an acid containing 1 to 6 carbon atoms, or (d) a carboxyl functional group in its free form or esterified by a lower alcohol containing 1 to 6 carbon atoms. (R' is a hydroxyl group) It can be represented by [this].

[0281] The peeling agent is preferably capryloyl salicylic acid.

[0282] The amount of (d) skincare active ingredient in the composition according to the present invention may be 0.001% by mass or more, preferably 0.005% by mass or more, and more preferably 0.01% by mass or more, based on the total mass of the composition.

[0283] On the other hand, the amount of (d) skincare active ingredient in the composition according to the present invention may be 20% by mass or less, preferably 15% by mass or less, and more preferably 10% by mass or less, based on the total mass of the composition.

[0284] Therefore, the amount of (d) skincare active ingredient in the composition according to the present invention may be 0.001% to 20% by mass, preferably 0.005% to 15% by mass, and more preferably 0.01% to 10% by mass, based on the total mass of the composition.

[0285] (Diol) The compositions according to the present invention may include (e) at least one diol having a total of five or six carbon atoms, with at least one carbon chain containing three or more carbon atoms. A single type of such diol or a combination of different types of such diols can be used.

[0286] In this specification, the term "diol" refers to a compound having two alcohol functional groups. In other words, a diol is an alcohol having two hydroxyl groups.

[0287] The number of carbon atoms in the carbon chain may be five or six.

[0288] (e) The carbon chain containing three or more carbon atoms in the diol may be linear or branched. The carbon chain is not interrupted by heteroatoms, such as oxygen, sulfur, and nitrogen atoms. Therefore, the carbon chain may contain continuous carbon atoms.

[0289] (e) Preferably, the number of carbon chains containing three or more carbon atoms in the diol is one or two.

[0290] (e) The total number of carbon atoms in the diol is 5 or 6.

[0291] (e) Diols having a total of 5 or 6 carbon atoms and having at least one carbon chain containing 3 or more carbon atoms may have divalent linear or branched hydrocarbon groups. (e) Divalent linear or branched hydrocarbon groups that may be present in the diol may be saturated or unsaturated. (e) Diols having a total of 5 or 6 carbon atoms and having at least one carbon chain containing 3 or more carbon atoms preferably contain divalent linear or branched saturated hydrocarbon groups, more preferably linear or branched alkylene groups, such as propylene, pentylene and hexylene groups.

[0292] (e) A diol having a total of 5 or 6 carbon atoms and having at least one carbon chain containing 3 or more carbon atoms may have a linear, branched or cyclic molecular structure, insofar as it has a carbon chain containing 3 or more carbon atoms and a total of 5 or 6 carbon atoms.

[0293] (e) Diols having a total of 5 or 6 carbon atoms, having at least one carbon chain containing 3 or more carbon atoms, are C2 containing 2 hydroxyl groups. 5~6 It could be a diol.

[0294] (e) Preferably, a diol having a total of 5 or 6 carbon atoms and having at least one carbon chain containing 3 or more carbon atoms is selected from the group consisting of dipropylene glycol, pentylene glycol, hexylene glycol, and mixtures thereof.

[0295] (e) It is more preferable that the diol having a total of 5 or 6 carbon atoms, having at least one carbon chain containing 3 or more carbon atoms, is selected from the group consisting of pentylene glycol, hexylene glycol, and mixtures thereof.

[0296] The amount of (e) diol described above may be 0.1% by mass or more, preferably 0.5% by mass or more, and more preferably 1% by mass or more, based on the total mass of the composition.

[0297] On the other hand, the amount of (e) diol may be 35% by mass or less, preferably 30% by mass or less, and more preferably 25% by mass or less, based on the total mass of the composition.

[0298] Therefore, the amount of (e) diol mentioned above may be 0.1% to 35% by mass, preferably 0.5% to 30% by mass, and more preferably 1% to 25% by mass, based on the total mass of the composition.

[0299] (water) The composition according to the present invention may contain (f) water.

[0300] (f) The amount of water may be 50% by mass or more, preferably 55% by mass or more, and more preferably 60% by mass or more, based on the total mass of the composition.

[0301] On the other hand, (f) the amount of water may be 99% by mass or less, preferably 98% by mass or less, and more preferably 97% by mass or less, relative to the total mass of the composition.

[0302] Therefore, (f) the amount of water may be 50% to 99% by mass, preferably 55% to 98% by mass, and more preferably 60% to 97% by mass, relative to the total mass of the composition.

[0303] (Monovalent nonpolymeric acid or its salt) The composition according to the present invention may contain (g) at least one monovalent nonpolymeric acid or a salt thereof. A single type of monovalent nonpolymeric acid or a salt thereof, or a combination of different types of monovalent nonpolymeric acids or salts thereof, can be used.

[0304] In this specification, the term "non-polymer" means that the acid is not obtained by polymerizing two or more monomers. Therefore, non-polymer acids do not correspond to acids obtained by polymerizing two or more monomers, such as polyacrylic acid.

[0305] In this specification, the term "salt" means a salt formed by adding a suitable base to a monovalent nonpolymeric acid, which can be obtained from the reaction of a monovalent nonpolymeric acid with a base according to methods known to those skilled in the art. Examples of salts include metal salts, such as salts with alkali metals like Na and K, and salts with alkaline earth metals like Mg and Ca, as well as ammonium salts.

[0306] (g) The molecular weight of the monovalent nonpolymeric acid or its salt is preferably less than 1000, preferably 500 or less, and more preferably 200 or less.

[0307] (g) Monovalent nonpolymeric acids or salts thereof may be included in the aqueous phase formed by (e) water. (g) Monovalent nonpolymeric acids or salts thereof can promote the dissolution of (c1) polysaccharides, preferably chitosan, more preferably high molecular weight chitosan, for example, in water.

[0308] (g) A monovalent nonpolymeric acid has a single acid group which can be selected from the group consisting of a carboxylic acid group, a sulfate group, a sulfonic acid group, a phosphoric acid group, a phosphonic acid group, and mixtures thereof.

[0309] (g) A monovalent nonpolymeric acid or a salt thereof may be selected from monovalent organic or inorganic acids and their salts.

[0310] (g) The monovalent nonpolymeric acid is preferably a monovalent organic acid, more preferably a monovalent nonpolymeric carboxylic acid.

[0311] The monovalent nonpolymeric carboxylic acid can be selected from hydroxy acids, preferably alpha-hydroxy acids and beta-hydroxy acids. Examples of alpha-hydroxy acids include lactic acid and glycolic acid. Examples of beta-hydroxy acids include salicylic acid.

[0312] Therefore, the monovalent nonpolymeric acid may be a monovalent nonpolymeric organic acid, preferably a monovalent nonpolymeric carboxylic acid, and more preferably a monovalent hydroxy acid, such as lactic acid and salicylic acid.

[0313] The amount of (g) monovalent nonpolymeric acid or its salt in the composition of the present invention may be 0.01% by mass or more, preferably 0.05% by mass or more, and more preferably 0.1% by mass or more, based on the total mass of the composition.

[0314] On the other hand, the amount of (g) monovalent nonpolymeric acid or salt thereof in the composition according to the present invention may be 15% by mass or less, preferably 10% by mass or less, and more preferably 5% by mass or less, based on the total mass of the composition.

[0315] Therefore, the amount of (g) monovalent nonpolymeric acid or its salt in the composition according to the present invention may be 0.01% to 15% by mass, preferably 0.05% to 10% by mass, and more preferably 0.1% to 5% by mass, based on the total mass of the composition.

[0316] (pH) The pH of the composition according to the present invention may be 3 to 9, preferably 3.3 to 8.5, and more preferably 3.5 to 8.

[0317] The pH of the composition according to the present invention can be adjusted by adding at least one alkaline agent and / or at least one acid. The pH of the composition according to the present invention can also be adjusted by adding at least one buffering agent.

[0318] (Optional additives) In addition to the components described above, the compositions according to the present invention may also contain components typically used in cosmetics, specifically cationic, anionic, amphoteric, or nonionic surfactants or emulsifiers; hydrophilic thickeners (other than (c1) polysaccharides); lipophilic thickeners; hydrophilic or lipophilic antioxidants; volatile or non-volatile organic solvents; silicones; natural extracts derived from animals or plants, etc., to the extent that they do not impair the effects of the present invention.

[0319] The composition according to the present invention may contain the above-mentioned optional additives in an amount of 0.01% to 30% by mass, preferably 0.05% to 20% by mass, and more preferably 0.1% to 10% by mass, based on the total mass of the composition.

[0320] The composition according to the present invention may contain a very limited amount of surfactant or emulsifier, taking environmental compatibility into consideration.

[0321] The amount of surfactant or emulsifier in the composition according to the present invention may be 1% by mass or less, preferably 0.1% by mass or less, and more preferably 0.01% by mass or less, based on the total mass of the composition. It is particularly preferable that the composition according to the present invention does not contain surfactant or emulsifier.

[0322] The composition according to the present invention may contain a very limited amount of silicone, taking environmental compatibility into consideration.

[0323] The amount of silicone in the composition according to the present invention may be 1% by mass or less, preferably 0.1% by mass or less, and more preferably 0.01% by mass or less, based on the total mass of the composition. It is particularly preferable that the composition according to the present invention does not contain silicone.

[0324] (Embodiment) According to a preferred embodiment, the composition according to the present invention is (a) at least one ceramide-type compound in an amount of 0.001% to 15% by mass, (b) At least one fatty compound selected from the group consisting of (b1) fatty acids, (b2) fatty alcohols, and mixtures thereof, in an amount of 0.01% to 15% by mass, 0.001% to 15% by mass of at least one compound selected from the group consisting of (c) (c1) polysaccharides, (c2) glycolipids, (c3) polyamino acids and their salts, (c4) proteins, and mixtures thereof. Includes.

[0325] According to a more preferred embodiment, the composition according to the present invention is (a') 0.005% to 10% by mass of (a') at least one ceramide-type compound represented by formula (I) above, (b') at least one fatty compound in an amount of 0.05% to 10% by mass, (b1')C4~C 24 Preferably C6~C 22 , more preferably C8~C 20 At least one fatty acid selected from saturated or unsaturated linear or branched fatty acids, (b2')C4~C 24 Preferably C6~C 22 , more preferably C8~C 20 At least one fatty alcohol selected from saturated or unsaturated linear or branched fatty alcohols, and those mixtures At least one fatty compound selected from the group consisting of, 0.005% to 10% by mass of at least one compound (c'), (c1') A polysaccharide selected from the group consisting of chitosan, hyaluronic acid and its derivatives, polysaccharides derived from microorganisms, and mixtures thereof, preferably from the group consisting of chitosan, hyaluronic acid and its salts, xanthan gum, and mixtures thereof. (c2') Glycolipids selected from the group consisting of rhamnolipids, sophorolipids, and mixtures thereof, (c3') Polyamino acids and salts selected from polyglutamic acid and its salts, (c4') Plant-derived proteins, and those mixtures At least one compound selected from the group consisting of and Includes.

[0326] According to a more preferred embodiment, the composition according to the present invention 0.01% to 5% by mass of (a) ceramide AP and / or ceramide NP, A fatty compound of (b) in an amount of 0.1% to 5% by mass, (b1) At least one fatty acid selected from oleic acid, linoleic acid, linolenic acid, palmitic acid, stearic acid, isostearic acid, and mixtures thereof, and (b2) At least one fatty alcohol selected from the group consisting of cetyl alcohol, cetearyl alcohol, stearyl alcohol, behenyl alcohol, oleyl alcohol, and mixtures thereof. At least one fatty compound selected from the group consisting of, A compound of at least one type (c) in an amount of 0.01% to 5% by mass, (c1") A polysaccharide selected from the group consisting of chitosan, hyaluronic acid and their salts, xanthan gum, and mixtures thereof, (c2") Glycolipids selected from the group consisting of rhamnolipid, sophorolipid, and mixtures thereof, (c3") Sodium polyglutamate, (c4") hydrolyzed soy protein, and At least one compound selected from the group consisting of mixtures thereof and Includes.

[0327] (preparation) The composition according to the present invention can be prepared by mixing the essential components described above with the optional components (if necessary) described above.

[0328] The methods and means for mixing the above-mentioned essential components and optional components are not limited. Any conventional methods and means may be used to mix the above-mentioned essential components and optional components to prepare the compositions according to the present invention.

[0329] The compositions according to the present invention can be prepared by simply or easily mixing using conventional mixing means such as a stirrer and a homogenizer. Heating may not be necessary. Therefore, the method for preparing the compositions according to the present invention may be environmentally friendly.

[0330] In one embodiment, the composition according to the present invention is (i) a step of preparing a diol solution by mixing (a) at least one ceramide-type compound, (b) at least one fatty compound selected from the group consisting of (b1) fatty acids, (b2) fatty alcohols, and mixtures thereof, and (c2) at least one glycolipid (if present) with (e) at least one diol having a total of 5 or 6 carbon atoms and having at least one carbon chain containing 3 or more carbon atoms, (ii) A step of preparing an aqueous solution by mixing (f) water with any one of (c1) at least one polysaccharide, (c3) at least one polyamino acid or a salt thereof, and (c4) at least one protein (if present), (iii) A step of preparing the composition according to the present invention by adding the diol solution obtained in step (i) to the aqueous solution obtained in step (ii), and It can be prepared by [method].

[0331] In the above process, (c2) at least one glycolipid, or (c1) at least one polysaccharide, (c3) at least one polyamino acid or its salt, and (c4) at least one protein may be used, or both (c2) at least one glycolipid and (c1) at least one polysaccharide, (c3) at least one polyamino acid or its salt, and (c4) at least one protein may be used.

[0332] The above process can be carried out, for example, at room temperature (25°C) or under elevated temperatures, for example, between 30°C and 90°C.

[0333] (Beauty use) The compositions according to the present invention may be intended for use as cosmetic compositions. Therefore, the cosmetic compositions according to the present invention may be intended for application to keratinous substances. In this specification, keratinous substances mean substances that contain keratin as a main component, and examples include skin, scalp, nails, lips, hair, etc. The cosmetic compositions according to the present invention are preferably used for cosmetic methods for keratinous substances, particularly for skin.

[0334] The compositions according to the present invention can preferably be used as cosmetic compositions, more preferably as cosmetic compositions for keratin substances, and even more preferably as skin cosmetic compositions for skin care.

[0335] (form) The composition according to the present invention may exist in any form.

[0336] For example, the composition according to the present invention may be in the form of a solution, particularly an aqueous solution, or a dispersion, particularly an aqueous dispersion.

[0337] [Beauty methods and usage] The present invention also, A cosmetic method for keratinous substances in the skin, etc. Steps of applying the composition according to the present invention to a keratin substance. This also includes information about beauty methods.

[0338] When the composition according to the present invention is applied to a keratinous substance such as skin, the microneedles in the composition can adhere to the keratinous substance, and therefore, components such as (a) ceramide-type compounds of the microneedles can be delivered to the deeper layers of the keratinous substance.

[0339] In this specification, "beauty treatment" refers to non-therapeutic beauty treatments for beautifying keratinous substances such as skin.

[0340] The present invention may also relate to the use of the composition according to the present invention as a cosmetic, such as in skincare products, or in cosmetic products.

[0341] In other words, the composition according to the present invention can be used as a cosmetic as is. Alternatively, the composition according to the present invention can be used as an element of a cosmetic. For example, the composition according to the present invention can be added to or combined with any other element to form a cosmetic.

[0342] For example, skincare products may include lotions and serums.

[0343] The present invention also includes (a) a composition comprising at least one ceramide-type compound, (b) The use of at least one fatty compound selected from the group consisting of (b1) fatty acids, (b2) fatty alcohols, and mixtures thereof, and (c) at least one compound selected from the group consisting of (c1) polysaccharides, (c2) glycolipids, (c3) polyamino acids and their salts, (c4) proteins, and mixtures thereof, which may also relate to a use for stabilizing the composition, and in particular preferably for stably dissolving or dispersing (a) ceramide-type compounds in the composition without aggregation of the (a) ceramide-type compounds.

[0344] The present invention also relates to the use of (a) at least one fatty compound selected from the group consisting of (b1) fatty acids, (b2) fatty alcohols, and mixtures thereof, and (c) at least one compound selected from the group consisting of (c1) polysaccharides, (c2) glycolipids, (c3) polyamino acids and their salts, (c4) proteins, and mixtures thereof, in a composition comprising (a) at least one ceramide-type compound, for forming at least one microneedle comprising (a) the ceramide-type compound having a width of 100 μm or less, preferably 50 μm or less, and more preferably 10 μm or less.

[0345] The above-described method and composition in use according to the present invention may further contain (d) at least one skincare active ingredient, and / or (e) at least one diol having a total of 5 or 6 carbon atoms, having at least one carbon chain containing 3 or more carbon atoms, and / or (f) water.

[0346] The above descriptions of (a) ceramide-type compounds, (b) fatty compounds, and (c) compounds in the compositions according to the present invention can be applied to those in the compositions in the above methods and uses according to the present invention.

[0347] [Method for preparing microneedles] In one embodiment, the present invention also relates to a method for preparing at least one type of microneedle, (i) a step of preparing a diol solution by mixing (a) at least one ceramide-type compound, (b) at least one fatty compound selected from the group consisting of (b1) fatty acids, (b2) fatty alcohols, and mixtures thereof, and (c2) at least one glycolipid (if present) with (e) at least one diol having a total of 5 or 6 carbon atoms and having at least one carbon chain containing 3 or more carbon atoms, (ii) A step of preparing an aqueous solution by mixing (f) water with any one of (c1) at least one polysaccharide, (c3) at least one polyamino acid or a salt thereof, and (c4) at least one protein (if present), (iii) A step of preparing a microneedle by adding the diol solution obtained in step (i) to the aqueous solution obtained in step (ii). Includes, The microneedle has a width of 100 μm or less, preferably 50 μm or less, and more preferably 10 μm or less. The microneedle contains (a) a ceramide-type compound, It also concerns the method.

[0348] In another embodiment, the present invention also, (i) a step of preparing a diol solution by mixing (a) at least one ceramide-type compound, (b) at least one fatty compound selected from the group consisting of (b1) fatty acids, (b2) fatty alcohols, and mixtures thereof, and (c2) at least one glycolipid (if present) with (e) at least one diol having a total of 5 or 6 carbon atoms and having at least one carbon chain containing 3 or more carbon atoms, (ii) A step of preparing an aqueous solution by mixing (f) water with any one of (c1) at least one polysaccharide, (c3) at least one polyamino acid or a salt thereof, and (c4) at least one protein (if present), (iii) A step of preparing a microneedle by adding the diol solution obtained in step (i) to the aqueous solution obtained in step (ii). A microneedle prepared by a method including, Having a width of 100 μm or less, preferably 50 μm or less, and more preferably 10 μm or less, (a) This also relates to microneedles containing ceramide-type compounds.

[0349] The above description of the compositions according to the present invention, relating to (a) ceramide-type compounds, (b) fatty compounds, (c) compounds, and (e) at least one diol having a total of 5 or 6 carbon atoms and having at least one carbon chain containing 3 or more carbon atoms, and / or (f) water, can be applied to the above method for preparing at least one microneedle according to the present invention.

[0350] In the above method, either (c2) at least one glycolipid, or (c1) at least one polysaccharide, (c3) at least one polyamino acid or its salt, and (c4) at least one protein, or both (c2) at least one glycolipid and (c1) at least one polysaccharide, (c3) at least one polyamino acid or its salt, and (c4) at least one protein can be used.

[0351] [Microneedle] In another embodiment, the present invention also, (a) at least one ceramide-type compound A microneedle containing, The present invention also relates to microneedles having a width of 100 μm or less, preferably 50 μm or less, and more preferably 10 μm or less.

[0352] The microneedle according to the present invention is (b) At least one fatty compound selected from the group consisting of (b1) fatty acids, (b2) fatty alcohols, and mixtures thereof, (c) At least one compound selected from the group consisting of (c1) polysaccharides, (c2) glycolipids, (c3) polyamino acids and their salts, (c4) proteins, and mixtures thereof, It may further include the following.

[0353] The minimum width of the microneedle is not limited and may be 0.1 μm or more, preferably 0.3 μm or more, and more preferably 0.5 μm or more.

[0354] Therefore, the width of the microneedle may be 0.1 μm to 100 μm, preferably 0.3 μm to 50 μm, and more preferably 0.5 μm to 10 μm.

[0355] The microneedle may have a certain width. Alternatively, the end of the microneedle may have a conical shape.

[0356] The microneedle may have an aspect ratio (length / width) of 4 or more, preferably 6 or more, and more preferably 8 or more.

[0357] The length of the microneedle is not limited and may be several micrometers or several hundred micrometers. Therefore, there is no upper limit to the aspect ratio of the microneedle. For example, the aspect ratio of the microneedle may be 100 or less, preferably 50 or less, and more preferably 10 or less.

[0358] The microneedles may be linear, curved, or bent nonlinear. A linear shape for the microneedles is preferred.

[0359] The above description of (a) ceramide-type compounds, (b) fatty compounds, and (c) compounds in the composition according to the present invention can be applied to the above-described microneedles according to the present invention. [Examples]

[0360] The present invention will be described in more detail by reference to examples. However, these should not be construed as limiting the scope of the present invention.

[0361] (Examples 1-9 and Comparative Example 1) [Preparation] Each of the compositions from Examples 1-9 and Comparative Example 1 was prepared by mixing the components shown in Table 1 below. All numerical values ​​for the amounts of components in Table 1 below are based on the "mass%" of the raw materials.

[0362] The details of the preparation are as follows:

[0363] A pentylene glycol solution was prepared by mixing ceramide, rhamnolipid / sophorolipid, and fatty acid / fatty alcohol (if present) with pentylene glycol (1,2-pentanediol) using a magnetic stirrer at 80°C for 15 minutes. Meanwhile, aqueous solutions were prepared by mixing the other components with water.

[0364] Pentylene glycol solution was added dropwise to an aqueous solution using a dispenser at 2000 rpm for 10 minutes while stirring at 80°C, and then cooled to room temperature (25°C) to obtain compositions according to Examples 1-9 and Comparative Example 1, respectively.

[0365] [Table 2]

[0366] [evaluation] (stability) Each of the compositions prepared in Examples 1-9 and Comparative Example 1 was stored in a transparent container at room temperature (25°C) immediately after preparation. The stability of each composition was observed visually and evaluated according to the following criteria. Good: No aggregation or precipitation was observed, or only slight aggregation or precipitation was observed. Poor performance: Aggregation or precipitation was observed.

[0367] The results are shown in Table 1 below.

[0368] (Microscopic observation) Each of the compositions from Examples 1-9 and Comparative Example 1 was subjected to microscopic observation at room temperature (25°C) immediately after composition preparation. Micrographs of each of the compositions from Examples 1-9 and Comparative Example 1 were obtained and observed. The fine structures in each micrograph were identified and characterized by the following symbols. N: Needle F / S: Foam / Separation

[0369] The results are shown in Table 1 below.

[0370] Microscopic images obtained by microscopic observation of the compositions according to Examples 1 to 9 are shown in Figures 1 to 9, respectively. It is clear that a complex in the form of microneedles has been formed.

[0371] In the composition of Comparative Example 1, no microstructure in the form of microneedles was found. In addition, the composition of Comparative Example 1 formed a foam and caused phase separation.

[0372] (Aspect ratio) The aspect ratio of the needles in the micrographs of each composition according to Examples 1 to 9 was determined by measuring the length and width of the needles, averaging the measured lengths and widths, and dividing the average length by the average width.

[0373] The results are shown in Table 1 below.

[0374] (summary) The compositions from Examples 1-9 were stable enough that no aggregation or precipitation was observed. Furthermore, the compositions from Examples 1-9 contained microneedle structures.

[0375] The composition according to Comparative Example 1, which contained no fatty compounds at all, was unstable. Furthermore, the composition according to Comparative Example 1 did not contain a microneedle structure.

Claims

1. (a) at least one ceramide-type compound, (b) At least one fatty compound selected from the group consisting of (b1) fatty acids, (b2) fatty alcohols, and mixtures thereof, (c) At least one compound selected from the group consisting of (c1) polysaccharides, (c2) glycolipids, (c3) polyamino acids and their salts, (c4) proteins, and mixtures thereof. A composition comprising, preferably a cosmetic composition, more preferably a skin cosmetic composition, The composition can form or contains at least one microneedle having a width of 100 μm or less, preferably 50 μm or less, and more preferably 10 μm or less. The microneedle contains (a) a ceramide-type compound, composition.

2. The composition according to claim 1, wherein the microneedles comprise (b) a fatty compound and (c) a compound.

3. The composition according to claim 1 or 2, wherein the microneedles have an aspect ratio of 4 or more, preferably 6 or more, and more preferably 8 or more.

4. (a) The ceramide-type compound is given by the following formula (I): 【Chemistry 1】 [In the formula, - R 1 C is a linear or branched saturated or unsaturated hydrocarbon group. 1 ~C 50 Preferably C 5 ~C 50 This represents a group which may be substituted with one or more hydroxyl groups and / or optionally interrupted with one or more oxycarbonyl (-O-CO-) groups or carbonyloxy (-CO-O-) groups. - R 2 represents a linear or branched, saturated or unsaturated hydrocarbon group C 1 to C 50 , preferably C 5 to C 50 , which group may be substituted with one or more hydroxyl groups, and / or may optionally be interrupted by one or more oxycarbonyl (-O-CO-) groups or carbonyloxy (-CO-O-) groups] The composition according to any one of claims 1 to 3, as represented by [the specified method].

5. The composition according to any one of claims 1 to 4, wherein the amount of (a) ceramide-type compound in the composition is 0.001% to 10% by mass, preferably 0.005% to 5% by mass, and more preferably 0.01% to 1% by mass, based on the total mass of the composition.

6. (b1) Fatty acids, C 4 ~C 24 Preferably C 6 ~C 22 , more C 8 ~C 20 A composition according to any one of claims 1 to 5, selected from saturated or unsaturated linear or branched fatty acids.

7. (b2) Fatty alcohols, C 4 ~C 24 Preferably C 6 ~C 22 , more C 8 ~C 20 A composition according to any one of claims 1 to 5, selected from saturated or unsaturated linear or branched fatty alcohols.

8. The composition according to any one of claims 1 to 7, wherein the amount of (b) fatty compound in the composition is 0.01% to 15% by mass, preferably 0.05% to 10% by mass, and more preferably 0.1% to 5% by mass, based on the total mass of the composition.

9. (c1) The composition according to any one of claims 1 to 8, wherein the polysaccharide is selected from the group consisting of chitosan, hyaluronic acid and its derivatives, polysaccharides derived from microorganisms, and mixtures thereof, preferably from the group consisting of chitosan, hyaluronic acid and its salts, xanthan gum, and mixtures thereof.

10. (c2) The composition according to any one of claims 1 to 9, wherein the glycolipid is selected from the group consisting of rhamnolipid, sophorolipid, and mixtures thereof, preferably selected from rhamnolipid.

11. (c3) The composition according to any one of claims 1 to 10, wherein the polyamino acid is selected from polyglutamic acid.

12. (c4) The composition according to any one of claims 1 to 11, wherein the protein is derived from a plant.

13. The composition according to any one of claims 1 to 12, wherein the amount of compound (c) in the composition is 0.001% to 15% by mass, preferably 0.005% to 10% by mass, and more preferably 0.01% to 5% by mass, based on the total mass of the composition.

14. A cosmetic method for keratinous substances in the skin, etc. A step of applying the composition according to any one of claims 1 to 13 to a keratin substance. Beauty methods, including

15. (a) at least one ceramide-type compound A microneedle containing, Having a width of 100 μm or less, preferably 50 μm or less, more preferably 10 μm or less, Microneedles.

16. (b) At least one fatty compound selected from the group consisting of (b1) fatty acids, (b2) fatty alcohols, and mixtures thereof, (c) At least one compound selected from the group consisting of (c1) polysaccharides, (c2) glycolipids, (c3) polyamino acids and their salts, (c4) proteins, and mixtures thereof. The microneedle according to claim 15, further comprising:

Images